How do we achieve blinding in modern electronic and paper medical records during the conduct of transfusion trials?

Sean Santos,Akash Gupta,Alan Tinmouth,Amir Butt,Brian Berry,Charles Musuka,Christine Cserti‐Gazdewich,Elaine Leung,Jennifer Duncan,Johnathan Mack,Matthew T. S. Yan,Mohammad Bahmanyar,Nadine Shehata,Oksana Prokopchuk‐Gauk,Rodrigo Onell,Susan Nahirniak,Thomas Covello,Yulia Lin,Ziad Solh,Jeannie Callum,Andrew W. Shih
DOI: https://doi.org/10.1111/trf.17738
2024-02-03
Transfusion
Abstract:Background Regulatory aspects of transfusion medicine add complexity in blinded transfusion trials when considering various electronic record keeping software and blood administration processes. The aim of this study is to explore strategies when blinding transfusion components and products in paper and electronic medical records. Methods Surveys were collected and interviews were conducted for 18 sites across various jurisdictions in North America to determine solutions applied in previous transfusion randomized control trials. Results Sixteen responses were collected of which 11 had previously participated in a transfusion randomized control trial. Various solutions were reported which were specific to the laboratory information system (LIS) and electronic medical record (EMR) combinations although solutions could be grouped into four categories which included the creation of a study product code in the LIS, preventing the transmission of data from the LIS to the EMR, utilizing specialized stickers and labels to conceal product containers and documents in the paper records, and modified bedside procedures and documentation. Discussion LIS and EMR combinations varied across sites, so it was not possible to determine combination‐specific solutions. The study was able to highlight solutions that may be emphasized in future iterations of LIS and EMR software as well as procedural changes that may minimize the risk of unblinding.
hematology
What problem does this paper attempt to address?